We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Olink Bioscience and Sapphire Bioscience Sign a Distributorship Agreement for the Australian & New Zealand Market

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Olink Bioscience has signed a distributorship agreement with Sapphire Bioscience for the distribution of the Duolink® product line in Australia and New Zealand.

“Sapphire Bioscience is a well established company with a strong presence in the Life Sciences market in Australia & New Zealand. With its strive to represent companies focused on cutting edge research, Sapphire Bioscience is a natural partner for us” says Peter Karlberg, Director of Sales and Marketing at Olink Bioscience.

“We are very pleased with the collaboration with Olink and the opportunity to offer the Duolink product line. Duolink is an enabling and innovative tool for studying e.g. cell signaling or transduction pathways and fits very well with our goal to provide first class reagents to the research community in Australia & New Zealand” says Sue Goodman, Business Manager at Sapphire Bioscience.

The Duolink product line is based on Olink Bioscience’s proprietary in situ PLA® a proximity ligation assay technology that extends the capabilities of traditional protein techniques. These capabilities include direct detection of proteins, protein interactions and modifications with unparalleled specificity and sensitivity.

Target proteins are detected with single molecule resolution, allowing digital quantification and information about the exact localization of the target. Furthermore, the proteins can be studied at normal expression levels in fixed cells and tissue sections.